

Characterization of the Eosinophilic Asthma Phenotype in a Global Real-Life Severe Asthma Cohort (International Severe Asthma Registry, ISAR) and Across All Asthma Severities in UK Primary Care

CHEST[®] JOURNAL

ASTHMA: ORIGINAL RESEARCH | VOLUME 160, ISSUE 3, P814-830, SEPTEMBER 01, 2021

Eosinophilic and Noneosinophilic Asthma

An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort



The Journal of Allergy and Clinical Immunology: In Practice Available online 14 August 2021 In Press, Corrected Proof 🕥



Original Articl

Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities








ISAR provides statistical power to better understand severe asthma epidemiology, clinical management and outcomes internationally









FeNO = Fractional exhaled nitric oxide; GINA = Global Initiative for Asthma; ICS = Inhaled corticosteroids; OCS = Oral corticosteroids GINA. Diagnosis and management of difficult-to-treat and severe asthma. https://ginasthma.org/severeasthma/. Accessed 30 September 2021.

Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

CHEST[®] JOURNAL

ASTHMA: ORIGINAL RESEARCH | VOLUME 160, ISSUE 3, P814-830, SEPTEMBER 01, 2021

Eosinophilic and Noneosinophilic Asthma

An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Click here for the article

Liam G. Heaney, Luis Perez de Llano, Mona Al-Ahmad, Vibeke Backer, John Busby, Giorgio Walter Canonica, George C. Christoff, Borja G. Cosio, J. Mark FitzGerald, Enrico Heffler, Takashi Iwanaga, David J. Jackson, Andrew N. Menzies-Gow, Nikolaos G. Papadopoulos, Andriana I. Papaioannou, Paul E. Pfeffer, Todor A. Popov, Celeste M. Porsbjerg, Chin Kook Rhee, Mohsen Sadatsafavi, Yuji Tohda, Eileen Wang, Michael E. Wechsler, Marianna Alacqua, Alan Altraja, Leif Bjermer, Unnur S. Björnsdóttir, Arnaud Bourdin, Guy G. Brusselle, Roland Buhl, Richard W. Costello, Mark Hew, Mariko Siyue Koh, Sverre Lehmann, Lauri Lehtimäki, Matthew Peters, Camille Taillé, Christian Taube, Trung N. Tran, James Zangrilli, Lakmini Bulathsinhala, Victoria A. Carter, Isha Chaudhry, Neva Eleangovan, Naeimeh Hosseini, Marjan Kerkhof, Ruth B. Murray, Chris A. Price, David B. Price



Background

- Severe asthma consists of different phenotypes and endotypes that differ in their clinical presentation, underlying pathways and response to treatment²
- Various classifications for the eosinophilic and non-eosinophilic phenotypes of severe asthma have been suggested; however, their clinical applicability in the real world is limited


Objectives

- 1. Develop an **algorithm** to characterize severe eosinophilic and non-eosinophilic asthma using both phenotypic characteristics and biomarkers
- 2. Quantify the **proportions** of patients with these phenotypes in ISAR
- 3. Describe and compare their demographics and clinical characteristics




Study design














Highest BEC Available (cells/µL)ª	Treatment or Clinical Characteristic	Eosinophilic Phenotype		Prospective ISAR Population (N = 1,716) [Original Algorithm]		Prospective ISAR Population (N = 1,716) [Original Algorithm Minus Age of Onset]		Prospective ISAR Population (N = 1,716) [Original Algorithm Minus FENO]		
				No. (%)	(%)	No. (%)	%	No. (%)	%	
≥ 300		Grade most likely	3: /	1,196 (69.7)		1,196 (69.7)		1,196 (69.7)		Meet likely ensigen
Anti-IL5 ≥ 150-< 300		Grade most likely	3:	178 ^b (10.4)	83.8	178 ^b (10.4)	82.6	178 ^b (10.4)	82.7	Most likely eosinopl
	Long-term OCS	Grade most likely	3: ,	37 (2.2)		37 (2.2)		37 (2.2)		
	Presence of \ge 2 of the following: NP, FENO \ge 25 ppb, or adult onset ^c (no long-term OCS)	Grade most likely	3: ′	27 (1.6)		7 (0.4)		8 (0.5)		
	Either NP, FENO ≥ 25 ppb or adult onset (no long-term OCS)	Grade likely	2:	67 (3.9)	3.9	45 (2.6)	2.6	71 (4.1)	4.1	
	No NP, elevated FENO, adult onset, or long-term OCS	Grade least likely	1:	27 (1.6)	1.6	69 (4.0)	4.0	42 (2.4)	2.4	
< 150	Long-term OCS	Grade likely	2:	75 (4.4)	4.4	75 (4.4)	4.4	75 (4.4)	4.4	
	Either NP, FENO ≥ 25 ppb or adult onset (no long-term OCS)	Grade least likely	1:	81 (4.7)	4.7	40 (2.4)	2.4	64 (3.7)	3.7	
	No NP, elevated FENO, adult onset, or long-term OCS	Grade unlikely (non- eosinophil	0:	28 (1.6)	1.6	69 (4.0)	4.0	45 (2.6)	2.6	Non-eosinophilic

st likely eosinophilic

IS/**R**








Grade 3: Most likely Grade 2: Likely Grade 1: Least likely Grade 0: Noneosinophlic



Patients with eosinophilic severe asthma were more likely to have poorer lung function and adult-onset asthma



Anti-IgE = Anti-immunoglobulin E; BEC = Blood eosinophil count; FeNO = Fractional exhaled nitric oxide; FEV1/FVC = ratio of forced expiratory volume in one second to forced vital capacity; LRTA = leukotriene receptor antagonist; ppb = parts per billion Heaney LG, Price D et al. CHEST 2021;3:814-830



IS/**R**



- The ISAR eosinophil phenotype algorithm was developed by expert consensus to characterize and quantify the eosinophilic and non-eosinophilic phenotypes of severe asthma patients in ISAR
- The eosinophilic phenotype was predominant in severe asthma
 - 83.8% of patients were most likely eosinophilic and 1.6% of patients were non-eosinophilic
 - Eosinophilic severe asthma was the most common phenotype globally
- Patients with eosinophilic severe asthma were more likely to have poorer lung function and adultonset asthma than those with non-eosinophilic severe asthma
- Asthma eosinophilic phenotyping can potentially lead to the identification of treatable traits and delivery of precision medicine in patients with severe asthma



Editorial



EDITORIAL | VOLUME 180, ISSUE 3, P789-790, SEPTEMBER 01, 2021 New Real-World Insights Into Severe Asthma All About the Eosinophil?

Click here for the editorial

Ramesh J. Kurukulaaratchy and Heena Mistry discussed the clinical importance of the ISAR eosinophilic gradient algorithm in characterizing severe asthma phenotypes in the real-world setting.¹

Podcast

Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort



Click here for the podcast

David B. Price and Ramesh J. Kurukulaaratchy, together with the *CHEST* podcast moderator Dominique Pepper, discussed the prevalence and characterization of eosinophilic and non-eosinophilic severe asthma phenotypes.²



Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities



The Journal of Allergy and Clinical Immunology: In Practice Available online 14 August 2021 In Press, Corrected Prof @



Original Article

Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities Marjan Kerkhof, Trung N. Tran, Riyad Allehebi, G. Walter Canonica, Liam G. Heaney, Mark Hew, Luis Perez de Llano, Michael E. Wechsler, Lakmini Bulathsinhala, Victoria A. Carter, Isha Chaudhry, Neva Eleangovan, Ruth B. Murray, Chris A. Price, David B. Price



Click here for the article

Background

- Asthma types should be characterized using phenotypic characteristics and biomarkers, to potentially identify treatable traits and deliver precision treatment
- Various classifications of asthma phenotypes in primary care have been proposed; however, they used variables that were not readily accessible in routine clinical practice or lacked characterization of underlying inflammatory disease pathways


Objectives

- Apply the ISAR eosinophil phenotype gradient algorithm² across all asthma severities in a UK primary care cohort
- 2. Quantify and characterize the eosinophilic and non-eosinophilic phenotypes in this cohort
- 3. Study the association between the likelihood of eosinophilic asthma phenotype severity and healthcare resource utilization



Study design








BEC = Blood eosinophil count; ISAR = International Severe Asthma Registry Kerkhof M, Price D et al. J Allergy Clin Immunol 2021; doi: 10.1016/j.jaip.2021.07.056


ISAR eosinophil phenotype algorithm applied to a UK primary care asthma cohort




Overall distribution									
Grade 3: Most likely	N=121,313 (50.3%)								
Grade 2: Likely	N=53,431 (22.2%)								
Grade 1: Less Likely	N=52,741 (21.9%)								
Grade 0: Unlikely	N=13,521 (5.6%)								

.. . ..





ISAR



Eosinophilic patients were more likely to have poorer asthma control and greater healthcare utilization than non-eosinophilic patients

— Non-eosinophilic (Grade 0; n=13,521) — Eosinophilic (Grade 3; n=121,313)



BEC = Blood eosinophil count; GINA = Global Initiative for Asthma; GP = General practice; ICS = Inhaled corticosteroid; PEF = Peak expiratory flow Kerkhof M, Price D et al. J Allergy Clin Immunol 2021; doi: 10.1016/j.jaip.2021.07.056



- The eosinophilic phenotype was predominant across all asthma severities in UK primary care
 - 72.5% of patients had most likely or likely eosinophilic phenotypes
 - 5.6% of patients were non-eosinophilic
- Patients with most likely eosinophilic asthma tended to have more comorbidities, poorer asthma control, and greater healthcare resource use than those with non-eosinophilic asthma
 - 28.2% of patients with most likely eosinophilic asthma versus 6.9% of patients with non-eosinophilic asthma had a Charlson comorbidity index of ≥2
 - 24.8% of patients with most likely eosinophilic asthma versus 15.3% of patients with non-eosinophilic asthma experienced ≥1 asthma attacks

• Asthma eosinophilic phenotyping should become part of routine clinical practice in primary care

 Patients with eosinophilic asthma phenotypes may benefit from earlier intervention with Type 2 targeted treatments, including ICS and steroid-sparing therapies such as biologics

